Pharma Focus Asia

Jubilant Therapeutics Announces Research Collaboration with The Wistar Institute to Evaluate the Activity of Novel PAD4 Inhibitors to Reduce Clinical Severity of COVID-19

Saturday, January 16, 2021

Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, announced a collaboration with The Wistar Institute, an international leader in biomedical research, to evaluate the ability of Peptidyl Arginine  Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms.

PAD4 is an enzyme that catalyzes conversion of arginine to citrulline in proteins, including histones and is highly expressed in neutrophils. Histone citrullination has been implicated in Neutrophil Extracellular Trap (NET) formation and accumulating evidence suggests that NETs may be linked to the severity of COVID-19, as their formation is a result of pro-inflammatory cytokine release syndrome (CRS), or cytokine storms, produced by the body's immune response to the SARS-CoV-2 virus. Cytokine storms are implicated in the development of acute respiratory distress syndrome (ARDS), which is the leading cause of death in patients infected with COVID-19.

"We are very pleased to announce our collaboration with the renowned Wistar Institute," said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics. "Even with COVID-19 vaccines on the horizon, we know its wrath will persist for some time to come and the need to reduce its death toll remains critical. Beyond COVID-19, understanding the potential of PAD4 inhibitors to address aberrant NET formation will be important due to their role in the pathogenesis of many disease states beyond viral infections."

"This collaboration with Jubilant Therapeutics will further advance our comprehensive research efforts to find therapeutics to diminish cytokine storms and decrease COVID-19 symptom gravity," said Yulia Nefedova, M.D., Ph.D., associate professor in the Immunology, Microenvironment & Metastasis Program at The Wistar Institute. "It is our hope that Jubilant Therapeutics' inhibitors will prove successful in blocking NET formation to this end."

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024